Download
car t preclinical in vivo assay n.
Skip this Video
Loading SlideShow in 5 Seconds..
in vivo animal testing PowerPoint Presentation
Download Presentation
in vivo animal testing

in vivo animal testing

2 Views Download Presentation
Download Presentation

in vivo animal testing

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. CAR-T Preclinical In Vivo Assay Reference: https://www.creative-biolabs.com/car-t/car-t-preclinical-in-vivo-assay.htm

  2. Introduction • CAR-T cells are autologous or allogeneic T cells targeting specifically to antigens or markers expressed by tumor cells. In vivo assessment is of pivotal importance for investigating the factors that may affect the efficacy of CAR-T cells. The approaches of delivering CAR genes into T cells, the in vitro culture conditions, the constituents of the CAR construct, and the types of host T cells all have great impacts on CAR-T efficacy and safety. Data from in vivo assays is valuable for CAR-T optimization.

  3. What can CAR-T cells do? • CAR-T cells capable of recognizing various tumor-associated antigens (TAAs) have been tested in many clinical trials and received plenty of encouraging results. However, several potential risks such as cytokine storm have also been posed for CAR-T cell clinical application. Therefore, preclinical in vivo assessment of the efficacy and safety of CAR-T cells are essential for dosage determination and risk managements for this promising immunotherapy against cancers.

  4. How to conduct in vivo assays? • CAR-T cell preclinical in vivo animal testing performed in xenograft murine models derived by well-defined cell lines or primary human tumor cells. • Immunodeficient mice, lacking of effective innate immunity for the absence of B cells, T cells, or NK cells, are the optimal animal models for engraftment of tumor cells and evaluation of CAR-T cells. • The progression and remission of tumor cells detected in any body part throughout the whole treatment duration, obtaining an unambiguous evaluation of the therapeutic efficacy of CAR-T cells. • A series of studies to investigate several potential safety concerns of CAR-T therapy including inappropriate immune activation (cytokine level), the potential for tumorigenicity, the risks of the delivery procedure, etc. • The in vivo expansion, survival, persistence, migration, and distribution of the CAR-T cells are also systematically studied.

  5. Featured in vivo Assay Categories • Construction of Xenograft Animal Model • Strategies to Harness Cytokine Release Syndrome • Efficacy Test of CAR-T • Viability and Bio-distribution Study of CAR-T • Toxicity Evaluation of CAR-T • Quality Control for in Vivo Assays

  6. Targets for CAR-T Preclinical in vivo Assays

  7. Thanks Reference: https://www.creative-biolabs.com/car-t/car-t-preclinical-in-vivo-assay.htm